News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cellectar Biosciences  (NVLT) Announces Receipt Of Orphan Designation Of I-124-CLR1404 As Diagnostic For The Management Of Glioma From FDA


5/5/2014 9:33:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MADISON, Wis., May 5, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that it has received notification from the U.S. Food and Drug Administration (FDA) granting Cellectar's request for orphan drug designation for I-124-CLR1404 as a diagnostic for the management of glioma, the most common and aggressive form of brain cancer.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES